Answering the need for rapid and precise fertility testing solutions.
There is a strong trend in the developed world to delay the decision to have children. This decision is often shifted to the late reproductive years. The delay in having children has increased the incidence of infertility1 and around 17.5% of the adult population (roughly 1 in 6 worldwide) experience infertility issues2. As a result, the use of assisted reproductive technology (ART) by infertile couples is increasing by 5–10% per year.3
Download a copy of the Siemens Healthineers Clinical Brief for information on:
- Importance of using an AMH assay with proven clinical performance and a specific cut-point for the estimation of high vs. lower ovarian reserve (OR)
- Data generated from two publications reviewing the Siemens Healthineers AMH assay and correlation and clinical performance compared to other available AMH assays
- Background and context for AMH testing, including testing in-vitro fertilization (IVF) patients
- Current guidelines and recommendations for assessing ovarian reserve (OR)
- Use of transvaginal ultrasound techniques vs. AMH and other hormonal testing
